Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

Craig L. Leonardi, Alexa B. Kimball, Kim A. Papp, Newman Yeilding, Cynthia Guzzo, Yuhua Wang, Shu Li, Lisa T. Dooley, Kenneth B. Gordon*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1280 Scopus citations

Fingerprint

Dive into the research topics of 'Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)'. Together they form a unique fingerprint.

Medicine & Life Sciences